Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 7/20 | 0.33 |
| ▸ | MMP13 | P45452 | 6/20 | 0.33 |
| ▸ | MMP1 | P03956 | 5/20 | 0.33 |
| ▸ | MMP3 | P08254 | 5/20 | 0.33 |
| ▸ | MMP9 | P14780 | 5/20 | 0.33 |
| ▸ | MMP7 | P09237 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18412644 | 0.79 | CA14 (0.43) | CA14CA12CA7CA9ADAM17 | |
| SCHEMBL13048839 | 0.79 | CA14 (0.43) | CA14CA12CA7CA9ADAM17 | |
| SCHEMBL5839738 | 0.79 | KDM4E (0.49) | CA14CA12MMP2MMP13MMP1 | |
| SCHEMBL13049836 | 0.79 | CA14 (0.43) | CA14CA12CA7CA9ADAM17 | |
| SCHEMBL5839741 | 0.79 | KDM4E (0.49) | CA14CA12MMP2MMP13MMP1 | |
| SCHEMBL1074659 | 0.77 | CA14 (0.42) | CA14CA12CA7CA9ADAM17 | |
| SCHEMBL1864824 | 0.77 | CA14 (0.42) | CA14CA12CA7CA9ADAM17 | |
| SCHEMBL158435 | 0.77 | CA14 (0.42) | CA14CA12CA7CA9ADAM17 | |
| SCHEMBL15491572 | 0.76 | CA14 (0.73) | CA14CA12CA7CA9MMP2 | |
| SCHEMBL21676278 | 0.74 | CA12 (0.39) | CA14CA12CA7CA9ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159460-A1 | Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease | ELAN PHARMACEUTICALS | 2005-07-21 | — | — | US | disclosed |
| EP-1450795-A1 | PEPTIDE ISOSTERES CONTAINING A HETEROCYCLE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003047576-A1 | PEPTIDE ISOSTERES CONTAINING A HETEROCYCLE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-0603309-A1 | PEPTIDE ISOTERS CONTAINING A HETEROCYCLE AS H.I.V. INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-06-29 | — | — | EP | disclosed |
| WO-1993005026-A1 | PEPTIDE ISOTERS CONTAINING A HETEROCYCLE AS H.I.V. INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159460-A1 | Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease | BACE1, APP, BACE2 | CA14 4044/4885CA12 3729/4885CA7 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.